Ono Pharmaceutical Co., Ltd. announced that they received supplemental approval in Japan for Braftovi (encorafenib) capsule in combination with cetuximab, an anti-human EGFR monoclonal antibody, and chemotherapy for… read more.
UCLA research finds that fewer than 1 in 4 eligible younger adults completed colorectal cancer screenings after the United States Preventive Services Task Force (USPSTF) lowered the recommended… read more.
Guardant Health Inc announced new real-world data published in Current Medical Research and Opinion finding that the Shield blood-based screening test demonstrates patient adherence of 95% in screening… read more.
A randomized controlled trial aimed to determine whether providing information on patient risk for advanced colorectal neoplasia (ACN) to patients and providers affects colorectal cancer (CRC) screening uptake…. read more.
In a new study aimed at identifying the best approach to promote colorectal cancer screening in adults ages 45 to 49, UCLA researchers found that simply mailing a… read more.
Pfizer Inc. announced positive results from the Phase III BREAKWATER trial evaluating Braftovi (encorafenib) in combination with cetuximab (Erbitux) and mFOLFOX6 (fluorouracil, leucovorin, and oxaliplatin) in patients with… read more.
Colorectal cancer screening is an effective tool for catching the disease early when it’s most treatable, yet it is underutilized in patient populations who receive primary care at… read more.
Trifluridine–tipiracil with bevacizumab is NICE recommended, within its marketing authorisation, for treating metastatic colorectal cancer in adults who have had 2 lines of treatment (including fluoropyrimidine-, oxaliplatin- and irinotecan-based… read more.
Regular aspirin may help lower risk of colorectal cancer in people with greater lifestyle-related risk factors for the disease, according to a study led by researchers at Mass… read more.
Geneoscopy, Inc., a life sciences company focused on developing diagnostic tests for the advancement of gastrointestinal health, announced that the FDA approved its noninvasive colorectal cancer screening test,… read more.
The rate of colorectal cancer screenings more than doubled when patients were given a choice between which type of screening they wanted—a take-home kit or colonoscopy—compared to those… read more.
Glucagon-like receptor agonists (GLP-1 RAs), a class of type 2 diabetes drug treatments, appear to also reduce the risk of colorectal cancer (CRC) researchers reported on Dec. 7,… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
